Press Releases

BioAlps annonce le lauréat de son prix : la famille Mauvernay, fondatrice de Debiopharm, une famille d’entrepreneurs au service de…

Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC25 inhibitor…

The Debiopharm Life Sciences Award goes to Dr Lluis Quintana-Murci for his novel and original research on the human evolutionary…

Debiopharm Group and Mercury Therapeutics, Inc. sign an exclusive license agreement for the development and commercialisation of Debio 0930 –…

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

Debiopharm and MSM Protein Technologies sign agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

Swissmedic grants Debiopharm marketing authorisation for Moapar® – A new therapeutic avenue for the treatment of sexual deviations

Salvacyl®, developed by Debiopharm, is launched in two European countries – a new therapeutic avenue for the treatment of sexual…

Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development…